KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Common Equity (2016 - 2026)

NovoCure's Common Equity history spans 13 years, with the latest figure at $330.7 million for Q1 2026.

  • On a quarterly basis, Common Equity fell 8.63% to $330.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $330.7 million, a 8.63% decrease, with the full-year FY2025 number at $340.5 million, down 5.47% from a year prior.
  • Common Equity hit $330.7 million in Q1 2026 for NovoCure, down from $340.5 million in the prior quarter.
  • Over the last five years, Common Equity for NVCR hit a ceiling of $445.4 million in Q3 2022 and a floor of $330.7 million in Q1 2026.
  • Historically, Common Equity has averaged $384.4 million across 5 years, with a median of $362.0 million in 2025.
  • Biggest five-year swings in Common Equity: grew 17.13% in 2022 and later dropped 17.83% in 2023.
  • Tracing NVCR's Common Equity over 5 years: stood at $441.2 million in 2022, then fell by 17.83% to $362.5 million in 2023, then decreased by 0.64% to $360.2 million in 2024, then dropped by 5.47% to $340.5 million in 2025, then fell by 2.86% to $330.7 million in 2026.
  • Business Quant data shows Common Equity for NVCR at $330.7 million in Q1 2026, $340.5 million in Q4 2025, and $341.3 million in Q3 2025.